Study of Intermittent Theta Burst Stimulation iTBS to Reduce Appetite Caused by Antipsychotics in Adults with Schizophrenia Aged 18 to 40
Led by Central South University · Updated on 2025-03-26
60
Participants Needed
2
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and effectiveness of intermittent theta burst stimulation iTBS in reducing increased appetite caused by antipsychotic medications in people with schizophrenia. The study addresses the metabolic side effects such as weight gain, high blood sugar, and cholesterol issues that raise the risk of death in these patients. It focuses on a less commonly studied iTBS mode compared to conventional repetitive transcranial magnetic stimulation rTMS.
Participants will be randomly assigned to receive either active or sham iTBS applied to the left dorsolateral prefrontal cortex. The active group will undergo 600 pulses of iTBS lasting 3 minutes, five times daily with 60-minute breaks, for 5 consecutive days. The sham group will receive a similar schedule without active stimulation. This treatment period is followed by monitoring at 2 and 4 weeks after intervention.
During the study, changes in appetite will be assessed using various questionnaires and a visual scale, while clinical symptoms, mood, and cognitive function will also be evaluated. Blood and feces samples will be collected to measure metabolic and neuroregulatory markers, including gut flora changes. Brain activity and blood flow will be monitored by MRI scans before and after treatment. Safety will be checked through symptom scales and adverse event records. The primary outcome is the change in body mass index BMI from baseline to 4 weeks post-treatment.
CONDITIONS
Brief Title
iTBS for Increased Appetite Induced by Antipsychotics
Research Team
R
Renrong Wu, M.D. Ph.D
J
Jing Huang, M.D. Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of schizophrenia according to DSM-5 criteria
Body mass index (BMI) of 25 kg/m2 or higher, or over 10% weight gain after antipsychotic use in the past year
No transcranial magnetic stimulation therapy in the past month
Using no more than two antipsychotic medications without antidepressants or mood stabilizers; short-term use of benzodiazepines, benzhexol, and propranolol allowed
Signed written informed consent voluntarily
You will not qualify if you...
Other severe mental illnesses, mental retardation, dementia, or severe cognitive impairment
Abnormal brain structure or function from major physical or neurological diseases or brain injury
Metallic implants, pacemakers, epilepsy history, or other contraindications for TMS
Suicidal thoughts or behaviors
Alcohol or substance abuse
Pregnant or breastfeeding women
Contraindications for MRI
Ongoing regular modified electroconvulsive therapy or weight-loss therapy in the past month
Other abnormal exam results deemed unsuitable by researchers
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 5 days
Participants receive intermittent theta burst stimulation or sham stimulation targeting the dorsolateral prefrontal cortex, with 5 sessions per day for 5 days.
Daily visits for 5 days
Follow-up
Duration - 4 weeks
Participants are monitored for changes in appetite, clinical symptoms, cognition, brain activity, metabolism, and adverse effects after completing the treatment.
Regular assessments at 2 weeks and 4 weeks post-treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Long-Term Safety and Tolerability Study of LB-102 in Adults With Stable Schizophrenia Over 52 Weeks
20-Year Follow-up Study on Early Treatment and Relapse Effects in First Episode Psychosis
Study Comparing Two Formulations of Paliperidone Palmitate Injection 3M in Chinese Adults with Schizophrenia
Randomized, Open-label, Multicenter, Multiple-dose Bioequivalence Study
A Phase 2 Study to Assess Safety and Effectiveness of Different Olanzapine Dosing Schedules in Adults with Schizophrenia
Long-term Study of SEP-363856 Tablets for Adults with Schizophrenia to Evaluate Safety and Tolerability
Open-Label Long-Term Study of ML-007C-MA for Adults with Schizophrenia Evaluating Safety and Effectiveness
Phase 1 Study of LY03020 Oral Tablets to Assess Safety, Tolerability, and Pharmacokinetics in Chinese Adults with Stable Schizophrenia or Healthy Volunteers
Evaluating Deep Transcranial Magnetic Stimulation dTMS for Reducing Antipsychotic-Induced Weight Gain in Schizophrenia Effects of Food Cue-Induced Craving in a Randomized, Crossover, Sham-Controlled Trial
Evaluating Brenipatide with Standard Care Compared to Placebo in Adults with Schizophrenia A Double-Blind, Randomized Phase 2 Study
Evaluating Safety and Early Effects of Oral LTX-001 Compared to Placebo in Adults With Worsening Schizophrenia Symptoms
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effects of intermittent theta burst stimulation (iTBS) on appetite change and body weight in inpatients with schizophrenia in China: study protocol for a randomised controlled trial.